
A 2026 analysis of MHRA AI Airlock Phase 2's seven cases, mapping intended purpose, AI-IVD validation, PCCPs and post-market evidence to practical UK development and NHS deployment decisions.
IntuitionLabs is now a member of the Claude Partner Network – AI training and upskilling with Claude for pharma and biotech. Book a call.

A 2026 analysis of MHRA AI Airlock Phase 2's seven cases, mapping intended purpose, AI-IVD validation, PCCPs and post-market evidence to practical UK development and NHS deployment decisions.

Compare HALO, Visiopharm, and Aiforia for preclinical pathology in 2026, including modalities, custom AI, GLP evidence, deployment, integration, cost questions, and a buyer-run bake-off.

Learn how AI pathology and deep-learning TME quantification link to postoperative ctDNA status and clinical outcomes in stage III colon cancer patients.

Analyze AstraZeneca's acquisition of Modella AI. Learn how multimodal foundation models integrate into oncology drug discovery and impact pharma AI M&A trends.

Review essential features of Anatomic Pathology LIMS, including digital pathology integration, compliance, and workflows for histopathology and cytology.

An overview of molecular pathology software, examining LIMS for NGS workflows, multi-omics data integration, and AI analysis tools in precision medicine.

An in-depth 2025 analysis of the leading medical imaging and digital pathology AI vendors. Covers market size, deep learning trends, and top company profiles.
© 2026 IntuitionLabs. All rights reserved.